ABSTRACT
Introduction Hashimoto’s Thyroiditis (HT) is a prevalent autoimmune disorder impacting thyroid function. Early detection allows for timely intervention and improved patient outcomes. Traditional diagnostic methods rely on clinical presentation and antibody testing, lacking a robust risk prediction tool.
Objective To develop a high-precision machine learning (ML) model for predicting the risk of HT development.
Method Data patients were acquired from PubMed. A binary classifier was constructed through data pre-processing, feature selection, and exploration of various ML models. Hyperparameter optimization and performance evaluation metrics (AUC-ROC, AUC-PR, sensitivity, specificity, precision, F1 score) were employed.
Results Out of a total of 9,173 individuals, 400 subjects within this cohort exhibited normal thyroid function, while 436 individuals were diagnosed with HT. The mean patient age was 45 years, and 90% were female. The best performing model achieved an AUC-ROC of 0.87 and AUC-PR of 0.85, indicating high predictive accuracy. Additionally, sensitivity, specificity, precision, and F1 score reached 85%, 90%, 80%, and 83% respectively, demonstrating the model’s effectiveness in identifying individuals at risk of HT development. Hyperparameter tuning was optimized using a Random Search approach.
Conclusion This study demonstrates the feasibility of utilizing ML for accurate prediction of HT risk. The high performance metrics achieved highlight the potential for this approach to become a valuable clinical tool for early identification and risk stratification of patients susceptible to HT.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
